Oncotarget is a medical journal published on weekly basis by Impact Journals. The peer-reviewed open access journal was established in 2010, covering oncology topics only. Its continued growth has seen it expand to accept papers from other topics including Neuroscience, Endocrinology, Cardiology, Metabolism, Cell Biology, and Pharmacology among others. Oncotarget has succeed to become one of the best free access journal. The goal of this multidisciplinary journal is to increase the impact of biomedical scientific research and promote the applicability of clinical science, which will significantly improve treatment of a diverse range of diseases.
The success of Oncotarget is driven by able scientific leaders who are committed to assist researchers develop advanced approaches of tackling diseases. Mikhail Blagosklonny is one of the key personalities propelling this noble course of disseminating scientific information that has greatly boosted collaboration among scientists. Mikhail is the Editor-in-Chief working alongside Andrei V. Gudkov.
Oncotarget is also available on Dove Press.
Mikhail Blagosklonny is a renowned scientist who has contributed immensely on aging and cancer disease. The Russian professor holds an M.D. in internal medicine and a PhD in experimental medicine and cardiology from Pavlov State Medical University. He launched his career at New York Medical College, Valhalla, NY as an associate professor where he was tasked with teaching medicine. In 2002, he moved to Ordway Research Institute to serve as a senior scientist. Later in 2009, he joined Roswell Park Cancer Institute as an oncology professor.
Mikhail, has developed keen interest in cancer therapies, aging process and targeted cancer therapies, which has seen him come up with hypothesis on Target of Rapamycin (TOR), which he believes to be the basis of cancer and aging. His extensive research also proposes Rapamycin as a possible cancer and life extension remedy.
Driven by a big vision of making the world disease-free, Mikhail Blagosklonny has been able to discover a lot in cellular and molecular biology. In addition to his active role in medicine, he is also the associate editor of a publication known as Cancer Biology & Therapy, and an active member of the editorial board for a publication known as Cell Death and Differentiation. He also serves as editor-in-chief of Aging and Cell Cycle.
Download output styles at Endnote.com